NASDAQ: CELC - Celcuity Inc.

六个月盈利: -8.53%
部门: Healthcare

促销时间表 Celcuity Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

更多详情
Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

Цена ао 17.52
EBITDA -0.0074
Число акций ао 0.02368 млрд
P/BV 6.1
EV/EBITDA -13.48
ISIN US15102K1007
Сайт https://www.celcuity.com
Валюта usd
IPO date 2017-09-20
Sector Health Care
Industry Biotechnology
Валюта отчета usd
每日价格变化: 0% (15.77)
每周价格变化: +9.74% (14.37)
每月价格变化: +5.27% (14.98)
3个月内价格变化: -10.65% (17.65)
六个月内的价格变化: -8.53% (17.24)
每年价格变化: +62.75% (9.69)
3年内价格变化: -5.63% (16.71)
5年内价格变化: -8.84% (17.3)
年初以来价格变化: +12.8% (13.98)
所有参数

低估

姓名 意义 年级
P/S 0 0
P/BV 2.54 6
P/E 0 0
EV/EBITDA -5.47 0
全部的: 3

效率

姓名 意义 年级
ROA, % -33.35 0
ROE, % -45.63 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.5632 10
全部的: 8

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 0 0
盈利能力 Ebitda, % 793.08 10
盈利能力 EPS, % 292.34 10
全部的: 8
更多详情

机构 体积 分享, %
Morgan Stanley 2195179 7.21
Soleus Capital Management, L.P. 2179481 7.16
VR Adviser, LLC 1885538 6.19
COMMODORE CAPITAL LP 1754704 5.76
Perceptive Advisors LLC 1481300 4.86
NEA Management Company, LLC 1250001 4.1
Blackrock Inc. 1050391 3.45
Vanguard Group Inc 820776 2.7
CapTrust Financial Advisors 544835 1.79
Baker Brothers Advisors, LLC 535478 1.76

ETF 分享, % 本年盈利能力, % 股息, %
Virtus LifeSci Biotech Clinical Trials ETF 0.76638 77.329244365683 0.33
ProShares Hedge Replication ETF 0.00212 6.8665973306333 1.47892
Humankind US Stock ETF 0.00221 22.971795629061 1.99919
iShares Morningstar Small-Cap ETF 0.00435 37.681332167863 1.60498
iShares Morningstar Small-Cap Growth ETF 0.00891 41.553945249597 0.72598
iShares Micro-Cap ETF 0.1014 43.316995205115 1.54048
iShares Russell 2000 Growth ETF 0.02744 47.42032299557 0.6026
iShares Russell 3000 ETF 0.00079 37.942616648456 1.43482
Jacob Forward ETF 0.85997 45.765428800427 0.15284
iShares Morningstar Small-Cap ETF 0.00435 410.50632631881 1.60498
iShares Morningstar Small-Cap Growth ETF 0.00891 757.51743375174 0.72598
ProShares UltraPro Russell2000 0.0075 125.96465921385 1.47873
Vanguard Russell 3000 ETF 0 38.467141890837 1.43817
Vanguard Russell 2000 Growth ETF 0.03 46.764050831914 0.60264
Vanguard Russell 2000 ETF 0.01 41.410408042578 1.48801



导师 职称 支付 出生年份
Mr. Brian F. Sullivan Co-Founder, Chairman & CEO 478.12k 1962 (62 年)
Dr. Lance G. Laing Ph.D. Co-Founder, Chief Science Officer, VP, Secretary & Director 389.55k 1962 (62 年)
Ms. Vicky Hahne Chief Financial Officer 281.59k 1966 (58 年)
Dr. John R. MacDonald Dabt, Ph., Ph.D. Senior Vice President of R&D N/A 1955 (69 年)
Ms. Sheri Smith Acting Head of Clinical Operations N/A
Mr. Igor Gorbatchevsky M.D. Chief Medical Officer N/A
Mr. Eldon C. Mayer III, M.B.A. Chief Commercial Officer N/A 1961 (63 年)
Dr. Charlotte Moser M.B.A., M.D., M.Sc., Ph.D. Senior Vice President of Clinical Development

地址: United States, Minneapolis. MN, 16305–36th Avenue North - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.celcuity.com